Publications

Register to Read

15 Aug 2006
First Look

First Look: August 15, 2006

expect bankers to have been less central than in Mexico and, perhaps, the United States. Second, I test if the availability of financing alternatives, like a well-developed bond market in Brazil, reduced the average importance of... View Details

Keywords: Sean Silverthorne

July 2000 (Revised November 2001)
Case

Catalyst Medical Solutions

By: Amy C. Edmondson, Richard M.J. Bohmer and Naomi Atkins

Faced with a drop in the NASDAQ, four eHealth entrepreneurs must decide between two distribution strategies for their new company's technology. The team, comprised of three full-time resident physicians and an MBA, has developed software to enable electronic... View Details

Keywords: Product Development; Health Care and Treatment; Distribution; Strategy; Venture Capital; Applications and Software; Partners and Partnerships; Borrowing and Debt; Information Technology Industry; Service Industry

Fall 2020
Article

Business Credit Programs in the Pandemic Era

By: Samuel G. Hanson, Jeremy C. Stein, Adi Sunderam and Eric Zwick

We develop a pair of models that speak to the goals and design of the sort of business-lending and corporate-bond purchase programs that have been introduced by governments in response to the ongoing COVID-19 pandemic. An overarching theme is that, in contrast to the... View Details

Keywords: COVID-19; Business Lending; Government Intervention; Econometric Models; Health Pandemics; Credit; Governance; Policy

Read Now

Article

Invisible Monuments and the Costs of Pharmaceutical Regulation: Twenty-Five Years of Drug Lag Debate

By: Arthur A. Daemmrich

Keywords: Cost; Health; Governing Rules, Regulations, and Reforms; Communication

February 2021
Supplement

HNA Group: Global Excellence with Chinese Characteristics (C)

By: William C. Kirby, Billy Chan and John P. McHugh

July 2017 was supposed to be a triumphant month for HNA Group. The latest Fortune Global 500 list showed the company had again skyrocketed in its ranking to no. 170, an improvement of over 200 positions from the year prior. Yet earlier that same July, the mysterious... View Details

Keywords: Conglomerate; Airline Industry; Coronavirus; Financial Risk; Debt; Bankruptcy; Global Strategy; Restructuring; Health Pandemics; Financial Markets; Organizational Change and Adaptation; Financial Condition; Globalized Firms and Management; Business and Government Relations; Air Transportation Industry; Financial Services Industry; China

October 2024
Article

Medicare Part D Protected-Class Policy Is Associated with Lower Drug Rebates

By: Pragya Kakani, Michael Anne Kyle, Amitabh Chandra and Luca Maini

Medicare Part D does not allow plans to exclude drugs in six protected classes from their formularies, which may limit plans’ ability to negotiate rebates and lead to higher spending. We estimated the association between protected-class status, US-level estimated... View Details

Keywords: Insurance; Health Care and Treatment; Governing Rules, Regulations, and Reforms; United States

March 2024
Article

Medicare Price Negotiation and Pharmaceutical Innovation Following the Inflation Reduction Act

By: Matthew Vogel, Pragya Kakani, Amitabh Chandra and Rena M. Conti

The Inflation Reduction Act (IRA) requires Medicare to negotiate lower prices for some medicines with high Medicare spending. Using historical data from public and proprietary sources to apply the IRA's negotiation criteria retrospectively, we identify all drugs that... View Details

Keywords: Policy; Government Legislation; Health Care and Treatment; Negotiation; Price; Pharmaceutical Industry

June 9, 2023
Article

A Radical Treatment for Insulin Pricing

By: Leemore S. Dafny

In 2021, the Food and Drug Administration (FDA) approved the first interchangeable biosimilar for long-acting insulin, which many hoped would be substantially cheaper than the reference branded product. I explain why prices have barely changed, and argue that a... View Details

Keywords: Biosimilars; Rebates; Pharmaceuticals; Health Care and Treatment; Price; Governing Rules, Regulations, and Reforms; Pharmaceutical Industry; United States

Register to Read

April 2018 (Revised September 2018)
Case

Impact Investing for Cancer

By: Richard G. Hamermesh and Matthew G. Preble

It is early 2018, and Emily Park, managing director of impact for the Abreu Family Office, is meeting the next day with Tomás and Maria Abreu to discuss the various ways in which the Abreus can allocate a planned $100 million to make a meaningful difference in cancer... View Details

Keywords: Impact Investing; Investment; Health Disorders; Philanthropy and Charitable Giving; Decision Choices and Conditions

Educators

September 2011
Teaching Note

Tengion: Bringing Regenerative Medicine to Life (TN)

By: Elie Ofek and Natalie Kindred

Teaching Note for 510031. View Details

Keywords: Partners and Partnerships; Production; Marketing; Cash; Health Care and Treatment; Medical Specialties; Research and Development; Biotechnology Industry

22 Mar 2016
First Look

March 22, 2016

investors have a positive impact on the growth, performance, and survival of firms as well as their follow-on fundraising. The positive impact of angel financing is independent of the level of venture activity and entrepreneur... View Details

Keywords: Sean Silverthorne

Article

Time-Driven Activity-Based Costing in Emergency Medicine

By: Robert S. Kaplan, Brian J. Yun, Anand M. Prabhakar, Jonathan Warsh, John Brennan, Kyle E. Dempsey and Ali S. Raja

Value in emergency medicine is determined by both patient-important outcomes and the costs associated with achieving them. However, measuring true costs is challenging. Without an understanding of costs, emergency department (ED) leaders will be unable to determine... View Details

Keywords: Time-Driven Activity-Based Costing; Emergency Room; Health Care and Treatment; Value; Cost Management; Activity Based Costing and Management

Read Now

14 Apr 2015
First Look

First Look: April 14

Applied Corporate Finance When One Size Doesn't Fit All: Evolving Directions in the Research and Practice of Enterprise Risk Management By: Mikes, Anette, and Robert S. Kaplan Abstract—Enterprise risk management (ERM) has become a crucial... View Details

Keywords: Sean Silverthorne

08 Dec 2009
First Look

First Look: Dec. 8

to be coupled with very low life satisfaction. Thus, people may work hard to maintain or increase their income in part because they overestimate the hedonic costs of earning low levels of income. Capital Market Driven Corporate Finance... View Details

Keywords: Martha Lagace

22 Aug 2005
Research & Ideas

Balancing the Future Against Today’s Needs

Urquhart, GE Commercial Finance Stanford Graduate School of Business professor Charles A. O'Reilly III and Harvard Business School professor Michael L. Tushman outline one approach in their Harvard Business Review article, "The... View Details

Keywords: by Paul Michelman

August 2012 (Revised August 2024)
Case

ABC Pharmaceuticals

By: Regina E. Herzlinger and Erik R. Sparks

This case asks students to price a new drug that is in Stage II of its clinical trials. It contains detailed estimates of the time required and costs for all the steps needed to commercialize a drug in the U.S. Students will learn virtually all the steps required to... View Details

Keywords: Drug Development; Price; Product; Product Launch; Health Industry; Health Industry; Health Industry

Educators